Skip to main content

Peer Review reports

From: RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using 47Sc-conjugated cetuximab

Original Submission
13 Nov 2022 Submitted Original manuscript
27 Mar 2023 Reviewed Reviewer Report
28 Mar 2023 Reviewed Reviewer Report
16 Apr 2023 Author responded Author comments - Da-Mi Kim
Resubmission - Version 2
16 Apr 2023 Submitted Manuscript version 2
21 Apr 2023 Author responded Author comments - Da-Mi Kim
Resubmission - Version 3
21 Apr 2023 Submitted Manuscript version 3
23 May 2023 Reviewed Reviewer Report
27 May 2023 Reviewed Reviewer Report
7 Jun 2023 Author responded Author comments - Da-Mi Kim
Resubmission - Version 4
7 Jun 2023 Submitted Manuscript version 4
20 Jun 2023 Reviewed Reviewer Report
5 Jul 2023 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
7 Jul 2023 Editorially accepted
12 Jul 2023 Article published 10.1186/s12885-023-11161-1

You can find further information about peer review here.

Back to article page